Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2002 15
2003 27
2004 25
2005 32
2006 27
2007 26
2008 26
2009 46
2010 28
2011 39
2012 41
2013 50
2014 36
2015 51
2016 53
2017 41
2018 36
2019 32
2020 44
2021 31
2022 30
2023 28
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

662 results

Results by year

Filters applied: . Clear all
Page 1
Association between loss of hypercoagulable phenotype, clinical features and complement pathway consumption in COVID-19.
Kasugai D, Tanaka T, Suzuki T, Ito Y, Nishida K, Ozaki M, Kutsuna T, Yokoyama T, Kaneko H, Ogata R, Matsui R, Goshima T, Hamada H, Ishii A, Kodama Y, Jingushi N, Ishikura K, Kamidani R, Tada M, Okada H, Yamamoto T, Goto Y. Kasugai D, et al. Among authors: ito y. Front Immunol. 2024 Mar 11;15:1337070. doi: 10.3389/fimmu.2024.1337070. eCollection 2024. Front Immunol. 2024. PMID: 38529277 Free PMC article.
Assessment of patients' characteristics associated with the efficacy and safety of oral valganciclovir treatment for infants with symptomatic congenital cytomegalovirus disease.
Kakei Y, Morioka I, Imai T, Itohara K, Yano I, Takahashi N, Yoshikawa T, Moriuchi H, Ito Y, Fujioka K, Oka A; Japanese Congenital Cytomegalovirus Study Group. Kakei Y, et al. Among authors: ito y. J Infect Chemother. 2024 Mar 13:S1341-321X(24)00081-3. doi: 10.1016/j.jiac.2024.03.006. Online ahead of print. J Infect Chemother. 2024. PMID: 38484931
A phase III randomized controlled trial comparing local field with additional prophylactic irradiation in chemoradiotherapy for clinical-T1bN0M0 esophageal cancer: ARMADILLO trial (JCOG1904).
Sasaki K, Nomura M, Kato K, Sakanaka K, Ito Y, Kadota T, Machida R, Kataoka T, Minashi K, Tsubosa Y, Kajiwara T, Fukuda H, Takeuchi H, Mizowaki T, Nishimura Y, Kitagawa Y. Sasaki K, et al. Among authors: ito y. Jpn J Clin Oncol. 2024 Jan 7;54(1):103-107. doi: 10.1093/jjco/hyad137. Jpn J Clin Oncol. 2024. PMID: 37801434 Clinical Trial.
662 results